MedTrace Logo

High Doses of Candesartan Cilexetil on the Reduction of Proteinuria

NCT00242346 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2007-12-19

No results posted yet for this study

Summary

The purpose of this study is to assess the effects of high doses of candesartan cilexetil and also to assess which dose (16mg, 64mg, 128mg) is the most optimal for the maximum reduction of proteinuria.

Conditions

  • Proteinuria

Interventions

DRUG

candesartan cilexetil

Sponsors & Collaborators

Principal Investigators

  • Kazi Borkowski, PhD · AstraZeneca

  • Norman MuirHead, MD · London HSC

  • Ellen Burgess, MD · Foothills Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Completion
2006-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00242346 on ClinicalTrials.gov